论文部分内容阅读
目的观察奥扎格雷联合长春西汀对脑卒中患者的临床疗效和安全性。方法 120例脑卒中患者随机分为试验组60例和对照组60例,2组患者均予以常规治疗。对照组在常规治疗基础上静脉滴注奥扎格雷钠160 mg qd,试验组在对照组基础上静脉滴注长春西汀30 mg qd,2组患者均连续用药14 d。比较2组患者临床疗效日常生活能力评分(ADL)、美国国立卫生院卒中量表(NIHSS)评分,并检测2组纤维蛋白原、凝血酶原时间、活化部分凝血凝血酶原时间(APTT)、血小板计数、血小板分布宽度、血小板平均体积及药物不良反应发生率。结果治疗后,试验组和对照组的总有效率分别为91.67%(55/60例)和76.7%(46/60例),ADL评分分别为(58.53±9.37),(53.52±8.80)分,NIHSS评分分别为(6.67±2.12),(8.28±2.83)分,血小板分布宽度分别为(17.41±3.60)%,(20.52±3.89)%,血小板平均体积分别为(7.12±0.43)%,(8.17±0.52)%,纤维蛋白原分别为(3.43±0.59),(3.75±0.68)g·L~(-1),差异均有统计学意义(均P<0.05)。试验组的药物不良反应主要有紫癜2例和皮疹1例,对照组的药物不良反应有皮疹1例。试验组和对照组的药物不良反应发生率分别为5.00%(3/60例)和1.67%(1/60例),差异无统计学意义(P>0.05)。结论奥扎格雷联合长春西汀能够抑制血小板活化,改善脑卒中患者神经功能,安全性较高。
Objective To observe the clinical efficacy and safety of ozagrel and vinpocetine in patients with stroke. Methods A total of 120 stroke patients were randomly divided into experimental group (60 cases) and control group (60 cases). Both groups were treated routinely. The control group received intravenous infusion of ozagrel sodium 160 mg qd on the basis of conventional treatment. The experimental group was given Vinpocetine 30 mg qd by intravenous infusion on the basis of the control group, and the patients in both groups were treated for 14 consecutive days. The ADR and NIHSS scores of two groups were compared and the levels of fibrinogen, prothrombin time, activated partial thromboplastin time (APTT) Platelet count, platelet distribution width, the average volume of platelets and the incidence of adverse drug reactions. Results After treatment, the total effective rates of the experimental group and the control group were 91.67% (55/60) and 76.7% (46/60), respectively. The ADL scores were (58.53 ± 9.37) and (53.52 ± 8.80) The NIHSS score was (6.67 ± 2.12) and (8.28 ± 2.83) respectively, the platelet distribution width was (17.41 ± 3.60)% and (20.52 ± 3.89)% respectively, and the average platelet volume was (7.12 ± 0.43)% and ± 0.52)%, and fibrinogen were (3.43 ± 0.59) and (3.75 ± 0.68) g · L -1, respectively (all P <0.05). Adverse drug reactions in the experimental group were mainly purpura in 2 cases and skin rash in 1 case, and adverse reactions in the control group were skin rash in 1 case. The incidence of adverse drug reactions in trial group and control group were 5.00% (3/60 cases) and 1.67% (1/60 cases), respectively, with no significant difference (P> 0.05). Conclusion Ozagrel combined with vinpocetine can inhibit platelet activation and improve neurological function in stroke patients with high safety.